- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 263/32 - Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Patent holdings for IPC class C07D 263/32
Total number of patents in this class: 586
10-year publication summary
|
38
|
31
|
36
|
38
|
37
|
38
|
31
|
26
|
22
|
5
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Otsuka Pharmaceutical Co., Ltd. | 1500 |
17 |
| Takeda Pharmaceutical Company Limited | 2726 |
11 |
| Bristol-myers Squibb Company | 4821 |
10 |
| Merck Sharp & Dohme LLC | 3719 |
10 |
| Pro Farm Group, Inc. | 124 |
10 |
| H. Lundbeck A/S | 1245 |
9 |
| Abbvie Inc. | 1848 |
8 |
| Canopy Growth Corporation | 212 |
8 |
| The Scripps Research Institute | 1346 |
8 |
| Hoffmann-La Roche Inc. | 3659 |
7 |
| Shionogi & Co., Ltd. | 830 |
7 |
| Calico Life Sciences LLC | 104 |
7 |
| F. Hoffmann-La Roche AG | 7847 |
6 |
| Toray Industries, Inc. | 7033 |
6 |
| Arcus Biosciences, Inc. | 151 |
6 |
| Argenta Discovery Ltd. | 36 |
6 |
| Oncternal Therapeutics, Inc. | 36 |
6 |
| Astellas Pharma Inc. | 1041 |
5 |
| Sanford Burnham Prebys Medical Discovery Institute | 305 |
5 |
| Taisho Pharmaceutical Co., Ltd. | 861 |
5 |
| Other owners | 429 |